Stevens-Johnson Syndrome (SJS) represents a life-threatening type IV hypersensitivity reaction involving the skin and mucous membranes. While several drugs frequently trigger this condition, co-amoxiclav-induced Stevens-Johnson Syndrome remains a relatively rare occurrence. A recent case report highlights this risk in a 98-year-old female who developed the syndrome following the administration of both intravenous and oral co-amoxiclav. Clinicians must maintain a high index of suspicion, even when using antibiotics generally considered safe.

Identifying Co-amoxiclav-induced Stevens-Johnson Syndrome

The diagnosis of SJS is primarily clinical, characterized by widespread desquamating rashes and mucosal erosions. In this specific case, the patient’s condition developed insidiously despite having tolerated the antibiotic during previous hospitalizations. This delayed onset suggests that prior exposure does not necessarily guarantee future safety. Consequently, healthcare providers must monitor elderly patients closely for any new skin changes after starting antimicrobial therapy. Moreover, the insidious nature of the rash can lead to delays in identifying the offending agent, which potentially worsens the prognosis.

Management Challenges in Geriatric Patients

Treating SJS in the elderly requires a delicate balance between aggressive immunosuppression and the management of comorbid conditions. For the 98-year-old patient, clinicians successfully used immunosuppressive therapies to control the reaction. However, the patient's frailty and denuded skin significantly increased the risk of secondary complications. Specifically, she suffered a serious urinary tract infection and a fall during her recovery period. Therefore, a multidisciplinary approach is essential for optimizing outcomes in older adults with SJS/TEN.

Clinical Pearls for Practice

Indian guidelines emphasize the prompt withdrawal of the offending agent as the most critical step in management. Supportive care, including fluid resuscitation and wound management, should follow immediately. Additionally, clinicians should educate patients and their families about the permanent avoidance of the culprit drug to prevent recurrence. Recognizing co-amoxiclav as a potential trigger ensures earlier intervention and potentially reduces the high mortality rates associated with this dermatological emergency. Notably, the risk window for drug-induced SJS typically spans 5 to 28 days after initiation, making vigilant follow-up crucial.

Frequently Asked Questions

What is the typical onset period for drug-induced SJS?

Most cases of Stevens-Johnson Syndrome occur between 5 and 28 days after the patient begins the offending medication. However, as seen in this case, the onset can sometimes be insidious and delayed, particularly in elderly populations with multiple comorbidities.

Is co-amoxiclav a common cause of SJS/TEN?

No, co-amoxiclav is generally considered a well-tolerated antibiotic with a good safety profile. While sulfonamides and anticonvulsants are the most frequent causes, co-amoxiclav is a recognized, albeit rare, trigger that clinicians must consider when a rash develops.

How should SJS be managed in an elderly patient?

Management involves immediate cessation of the suspected drug, supportive care in a specialized unit, and the judicious use of immunosuppressants. In the elderly, clinicians must also prioritize the prevention of secondary infections and falls due to increased frailty.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Baldacchino G et al. A case of delayed-onset Stevens-Johnson syndrome following co-amoxiclav administration in a 98-year-old female. Int J Risk Saf Med. 2026 Feb 17. doi: 10.1177/09246479261426749. PMID: 41701991.


2. Guidelines for the management of Stevens–Johnson syndrome/toxic epidermal necrolysis: An Indian perspective. Indian J Dermatol Venereol Leprol. 2016 Nov-Dec;82(6):603-625.


3. Patel TK et al. Amoxycillin and clavulanic acid induced Stevens-Johnson syndrome: A case report. J Young Pharmacists. 2021;13(1):76-78.